Forte Biosciences (FBRX) Competitors $12.54 -0.07 (-0.56%) As of 02:08 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FBRX vs. FHTX, SLRN, DSGN, URGN, CRDF, CGC, PROK, GNFT, DBVT, and AVTEShould you be buying Forte Biosciences stock or one of its competitors? The main competitors of Forte Biosciences include Foghorn Therapeutics (FHTX), Acelyrin (SLRN), Design Therapeutics (DSGN), UroGen Pharma (URGN), Cardiff Oncology (CRDF), Canopy Growth (CGC), ProKidney (PROK), Genfit (GNFT), DBV Technologies (DBVT), and Aerovate Therapeutics (AVTE). These companies are all part of the "pharmaceutical products" industry. Forte Biosciences vs. Its Competitors Foghorn Therapeutics Acelyrin Design Therapeutics UroGen Pharma Cardiff Oncology Canopy Growth ProKidney Genfit DBV Technologies Aerovate Therapeutics Forte Biosciences (NASDAQ:FBRX) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, community ranking, risk, earnings, dividends and valuation. Does the media prefer FBRX or FHTX? In the previous week, Forte Biosciences had 4 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 6 mentions for Forte Biosciences and 2 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 0.93 beat Forte Biosciences' score of 0.45 indicating that Foghorn Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forte Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Foghorn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor FBRX or FHTX? Foghorn Therapeutics received 16 more outperform votes than Forte Biosciences when rated by MarketBeat users. Likewise, 66.20% of users gave Foghorn Therapeutics an outperform vote while only 60.78% of users gave Forte Biosciences an outperform vote. CompanyUnderperformOutperformForte BiosciencesOutperform Votes3160.78% Underperform Votes2039.22% Foghorn TherapeuticsOutperform Votes4766.20% Underperform Votes2433.80% Which has more volatility & risk, FBRX or FHTX? Forte Biosciences has a beta of 2.85, indicating that its share price is 185% more volatile than the S&P 500. Comparatively, Foghorn Therapeutics has a beta of 3.04, indicating that its share price is 204% more volatile than the S&P 500. Which has preferable valuation and earnings, FBRX or FHTX? Forte Biosciences has higher earnings, but lower revenue than Foghorn Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioForte BiosciencesN/AN/A-$31.48M-$16.29-0.77Foghorn Therapeutics$23.50M11.00-$98.43M-$1.36-3.41 Do analysts recommend FBRX or FHTX? Forte Biosciences currently has a consensus price target of $61.00, indicating a potential upside of 386.44%. Foghorn Therapeutics has a consensus price target of $12.13, indicating a potential upside of 161.31%. Given Forte Biosciences' higher possible upside, analysts clearly believe Forte Biosciences is more favorable than Foghorn Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Forte Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Foghorn Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.13 Is FBRX or FHTX more profitable? Forte Biosciences has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -357.53%. Foghorn Therapeutics' return on equity of 0.00% beat Forte Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Forte BiosciencesN/A -151.43% -118.92% Foghorn Therapeutics -357.53%N/A -30.98% Do institutionals and insiders believe in FBRX or FHTX? 77.6% of Forte Biosciences shares are owned by institutional investors. Comparatively, 61.5% of Foghorn Therapeutics shares are owned by institutional investors. 5.9% of Forte Biosciences shares are owned by insiders. Comparatively, 7.6% of Foghorn Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryFoghorn Therapeutics beats Forte Biosciences on 12 of the 18 factors compared between the two stocks. Get Forte Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for FBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FBRX vs. The Competition Export to ExcelMetricForte BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$82.55M$6.94B$5.60B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-0.778.8427.2520.00Price / SalesN/A265.40413.35158.30Price / CashN/A65.8538.2534.64Price / Book0.526.617.124.70Net Income-$31.48M$144.20M$3.24B$248.14M7 Day Performance21.16%4.00%2.71%2.48%1 Month Performance99.68%11.33%8.93%6.15%1 Year PerformanceN/A3.91%31.30%13.59% Forte Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FBRXForte Biosciences3.0176 of 5 stars$12.54-0.6%$61.00+386.4%+54,210.3%$82.55MN/A-0.775Options VolumeGap UpFHTXFoghorn Therapeutics2.1924 of 5 stars$4.17+2.2%$12.13+190.8%-23.2%$232.44M$23.50M-2.17120SLRNAcelyrin2.9673 of 5 stars$2.27flat$9.60+322.9%N/A$229.17MN/A-0.92135Positive NewsDSGNDesign Therapeutics0.6332 of 5 stars$4.02+7.8%$4.00-0.5%-3.2%$228.21MN/A-4.7340Positive NewsURGNUroGen Pharma4.6849 of 5 stars$4.84+14.2%$27.43+466.7%-44.2%$223.16M$91.87M-1.54200Trending NewsAnalyst ForecastShort Interest ↓Trading HaltedHigh Trading VolumeCRDFCardiff Oncology1.8383 of 5 stars$3.35-1.8%$12.00+258.2%+31.2%$222.86M$587K-3.5620CGCCanopy Growth2.3853 of 5 stars$1.21-8.3%$2.00+65.3%-78.6%$222.48M$276.75M-0.323,150Gap UpHigh Trading VolumePROKProKidney2.4598 of 5 stars$0.75+3.2%$5.00+570.3%-61.4%$218.32M$306K-1.363Positive NewsGap DownGNFTGenfit2.5725 of 5 stars$4.34-3.8%$13.00+199.7%-17.0%$216.83M$67.00M0.00120Positive NewsShort Interest ↓DBVTDBV Technologies3.4424 of 5 stars$7.74-7.3%$14.75+90.6%+72.7%$212.00M$15.73M-1.7280News CoverageGap UpAVTEAerovate Therapeutics1.8506 of 5 stars$7.25+2.3%$78.75+986.2%-99.1%$210.14MN/A-2.4220Positive NewsHigh Trading Volume Related Companies and Tools Related Companies FHTX Competitors SLRN Competitors DSGN Competitors URGN Competitors CRDF Competitors CGC Competitors PROK Competitors GNFT Competitors DBVT Competitors AVTE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FBRX) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Forte Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Forte Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FBRX Stock Free FBRX Stock Alerts